Correlation Engine 2.0
Clear Search sequence regions


  • antigens (1)
  • b cell (2)
  • b cell lymphoma (1)
  • BCR (1)
  • cancer (2)
  • CDR3 (4)
  • human cell (1)
  • leukaemia (1)
  • mrna (4)
  • patients (1)
  • receptor (2)
  • t cell (3)
  • t cell lymphoma (3)
  • t cell receptor (1)
  • t cell receptor (1)
  • TCR (6)
  • Tumour (1)
  • vaccines (1)
  • Sizes of these terms reflect their relevance to your search.

    Efficient vaccination can be achieved by injections of in vitro transcribed mRNA (ivt mRNA) coding for antigens. This vaccine format is particularly versatile and allows the production of individualised vaccines conferring, T-cell immunity against specific cancer mutations. The CDR3 hypervariable regions of immune receptors (T-cell receptor, TCR or B-cell receptor, BCR) in the context of T- or B-cell leukaemia or lymphoma are targetable and specific sequences, similar to cancer mutations. We evaluated the functionality of an mRNA-based vaccine designed to trigger immunity against TCR CDR3 regions in an EL4 T-lymphoma cell line-derived murine in vivo model. Vaccination against the hypervariable TCR regions proved to be a feasible approach and allowed for protection against T-lymphoma, even though immune escape in terms of TCR downregulation paralleled the therapeutic effect. However, analysis of human cutaneous T-cell lymphoma samples indicated that, as is the case in B-lymphomas, the clonotypic receptor may be a driver mutation and is not downregulated upon treatment. Thus, vaccination against TCR CDR3 regions using customised ivt mRNA is a promising immunotherapy method to be explored for the treatment of patients with T-cell lymphomas.

    Citation

    Marina Tusup, Severin Läuchli, Natalia Teresa Jarzebska, Lars E French, Yun-Tsan Chang, Maya Vonow-Eisenring, Andreas Su, Thomas M Kündig, Emmanuella Guenova, Steve Pascolo. mRNA-Based Anti-TCR CDR3 Tumour Vaccine for T-Cell Lymphoma. Pharmaceutics. 2021 Jul 07;13(7)


    PMID: 34371731

    View Full Text